报价延迟最少15分钟:2026/09/05 17:23 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.32 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.44/0.06
|
|
企业价值
2.34B
|
| 资产负债 |
|
每股账面净值
4.38
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
120.25M
|
|
每股收益
0.06
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low backpain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform. |
